Calithera Biosciences, Inc. (CALA) Raised to Neutral at Citigroup Inc.

Calithera Biosciences, Inc. (CALA) Raised to Neutral at Citigroup Inc.

Citigroup Inc. upgraded shares of Calithera Biosciences, Inc. (NASDAQ:CALA) from a sell rating to a neutral rating in a research note published on Tuesday. They currently have $5.00 price target on the stock.

A number of other brokerages have also recently commented on CALA. HC Wainwright initiated coverage on shares of Calithera Biosciences in a research report on Thursday, January 5th. They issued a buy rating and a $9.00 target price for the company. JMP Securities reiterated a buy rating on shares of Calithera Biosciences in a research report on Thursday, December 1st. Finally, Zacks Investment Research upgraded shares of Calithera Biosciences from a hold rating to a buy rating and set a $3.75 target price for the company in a research report on Monday, November 14th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Calithera Biosciences has a consensus rating of Buy and a consensus target price of $8.35.

Calithera Biosciences (NASDAQ:CALA) traded down 0.538% during midday trading on Tuesday, reaching $4.625. 20,679 shares of the company’s stock traded hands. The company’s market capitalization is $95.91 million. Calithera Biosciences has a 1-year low of $2.20 and a 1-year high of $6.87. The firm’s 50-day moving average is $3.82 and its 200-day moving average is $3.29.

In other news, major shareholder Adage Capital Partners Gp, L.L acquired 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 16th. The stock was purchased at an average cost of $3.15 per share, for a total transaction of $1,575,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 27.50% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP raised its position in shares of Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock valued at $162,000 after buying an additional 9,000 shares during the period. Franklin Street Advisors Inc. NC raised its position in shares of Calithera Biosciences by 18.6% in the third quarter. Franklin Street Advisors Inc. NC now owns 100,000 shares of the company’s stock valued at $325,000 after buying an additional 15,700 shares during the period. Paloma Partners Management Co bought a new position in shares of Calithera Biosciences during the second quarter valued at $150,000. D. E. Shaw & Co. Inc. raised its position in shares of Calithera Biosciences by 119.1% in the third quarter. D. E. Shaw & Co. Inc. now owns 81,613 shares of the company’s stock valued at $265,000 after buying an additional 44,364 shares during the period. Finally, Bridgeway Capital Management Inc. raised its position in shares of Calithera Biosciences by 102.8% in the second quarter. Bridgeway Capital Management Inc. now owns 157,850 shares of the company’s stock valued at $586,000 after buying an additional 80,000 shares during the period. 40.33% of the stock is owned by institutional investors.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Related posts

Leave a Comment